Announcements

Ms. Abigayle (Abbey) Vito, a third-year graduate student in Dr. Bret Freudenthal’s lab at the University of Kansas Medical Center, won the poster award at the 7th DNA Repair/Replication Structures & Cancer Conference, sponsored by the Journal Cluster of Oncology, and we had the privilege of speaking with her. Below, she shares insights into her academic journey, research focus, and the motivation behind her landmark study.

1. Could you briefly introduce yourself and your main research focus within the broad area of DNA repair, replication structures, or cancer biology?
My name is Abigayle (Abbey) Vito, and I am a third-year graduate student in Dr. Bret Freudenthal’s lab at the University of Kansas Medical Center. My research focuses on understanding how DNA repair occurs within the complex chromatin environment of human cells. Much of the biochemical work that has laid the foundation for our knowledge of DNA repair has been performed on short DNA oligonucleotides. However, DNA in human cells is much more complex and is condensed into chromatin through the fundamental unit known as the nucleosome. My research goal is to understand how DNA repair, specifically base excision repair (BER), operates within chromatin. To address this goal, I utilize the nucleosome as a model system and use structural biology to elucidate the molecular mechanism that BER enzymes use to engage their substrates. This work fundamentally enhances our understanding of how DNA repair is carried out within human cells. 
 
2. What do you think made your poster stand out—the scientific novelty, the clarity of the story, the visual presentation, or something else?
It was an incredible experience to attend a conference with so many structural biologists, from trainees to experts in the field. Based on the feedback I received during the poster session, I believe that my poster stood out for its clarity and the number of novel structures presented. I think, as structural biologists, we get very excited to see new structures from other researchers in the field because they can provide a lot of new insight into proteins that we are invested in understanding.
 
3. Any advice for early career researchers preparing their first poster?
The most important piece of advice that I have received about making a poster is that it is not necessary to present every piece of data that you have collected. It is much more impactful to have a visually appealing poster with a logical flow and only share the most important aspects of your story. Getting to the central point of your story quickly allows time for more meaningful conversations with audience members, which can lead to new perspectives on your research or experiments you may be struggling with.
 
4. Looking beyond the poster, what are the next steps for this research? Are you planning to follow up with a full paper?
This poster was only the beginning of a very exciting project! Along with structural data showing how BER enzymes engage their substrates, I am very interested in understanding how these enzymes locate their substrates to begin with. The nucleus of human cells contains over 3 billion base pairs of DNA, and these proteins face the extraordinarily difficult task of finding the specific lesion that they need to process. We are excited to use a single-molecule approach to investigate the mechanisms used by BER proteins to search for DNA damage. Looking further ahead, we hope to translate this into human cells to better understand how these enzymes protect against DNA-damaging agents that drive cancer. 
 
5. Our journal has always been committed to promoting high-quality research in DNA repair/replication and cancer biology. Would you be interested in working with us? What kind of support would be most helpful for you in that process?
I would absolutely be interested in working with the journal! As my project develops, I hope to submit a research article encompassing both the structural and single-molecule findings from this work. Having a journal with a strong commitment to DNA repair and cancer biology would be a great fit for this story. As for support, having guidance through the submission and revision process would be most helpful. In particular, workshops that address the technical aspects of manuscript submission and the editorial/peer review process would be very beneficial for early-career researchers like myself.

On 8 May 2026, MDPI Canada & USA welcomed over 40 researchers, clinicians, and oncology professionals to our Subject Workshop, “Cutting-Edge Advances in Cancer Immunology and Immunotherapy: From Basic Science to Clinical Impact”, held at the HSC Conference Center in Los Angeles, California.

	Our workshop host, Bob Vrooman, Head of Business Development at MDPI USA, opened the event and emphasized the importance of advancing cancer care. He introduced the workshop chair, Dr. W. Martin Kast, highlighting his achievements in immunology and cancer research.
	Dr. W. Martin Kast welcomed attendees, emphasizing the transformative impact of cancer immunotherapy and the challenges that remain.
	Then, MDPI Canada & USA’s Operating Director, Elvis Wang, emphasized the company's core values of transparency, service, and integrity. Furthermore, he explained the importance of collaboration in scientific research.

The day’s presentations were full of exciting discussion as ten speakers discussed their research findings. These presenters included Dr. Abhinava Mishra, Dr. Alan L. Epstein, Dr. De-Chen Lin, Dr. Casey O’Connell, Dr. Henry K. Wong, Dr. Hossein Jadvar, Dr. Kawaljit Kaur, Dr. Lili Yang, Dr. W. Martin Kast, and Dr. Sonia Sharma.

The presentations included topics such as immune checkpoint blockade therapy, CAR-T and CAR-macrophage therapies, and the role of NK cells in cancer therapy. Furthermore, presentations focused on how epigenetic mutations reshape T-cell behavior.

The second half of the day included presentations covering imaging treatment response criteria and multimodal single-cell analysis. Further presentations focused on the treatment of cutaneous T-cell lymphomas (CTCLs) and the development of therapeutic vaccines to treat HPV-associated cancers.

Dr. Sheridan Baker, a representative of MDPI, covered MDPI's role in supporting open science and MDPI’s publishing trends in oncology. His presentation allowed audience members to further understand how MDPI can support researchers working within a variety of research areas.

During the day’s proceedings, multiple Q&A sessions were held, allowing valuable engagement between speakers and attendees. These sessions were a highlight of the event and helped build a platform for meaningful scientific exchange.

Looking Ahead

The MDPI 2026 LA Subject Workshop “Cutting-Edge Advances in Cancer Immunology and Immunotherapy: From Basic Science to Clinical Impact” was a successful collaboration between MDPI and local academics. We are thankful to all attendees for their part in making this event possible and for contributing to its success.

We have received positive feedback regarding this event and look forward to continuing to host these Subject Workshops. For more updates regarding this event and other upcoming workshops, follow MDPI Canada on LinkedIn.

As part of its continued efforts to support impactful cancer research and foster scientific dialogue, MDPI is spotlighting head and neck cancer in this edition. Encompassing a diverse group of malignancies affecting the oral cavity, pharynx, and larynx, head and neck cancers collectively account for over 900,000 new cases and more than 400,000 deaths globally each year.

In recent years, shifting epidemiological patterns, particularly the rise of HPV-associated cancers, have introduced new challenges and opportunities in both research and clinical practice. These developments call for deeper insights into disease mechanisms, as well as more precise approaches to diagnosis, treatment, and patient stratification.

By bringing together cutting-edge research, focused Special Issues, and an expert-led webinar, MDPI journals aim to continue to facilitate knowledge exchange and highlight emerging advances in the field. These efforts play an important role in advancing innovation, improving early detection and therapeutic strategies, and ultimately enhancing outcomes for patients worldwide.

Keynote speakers
Dr. Kousik Kumar Kesh, St. Louis University, USA	Prof. Dr. Richard Yuxiong Su, The University of Hong Kong, Hong Kong S.A.R	Dr. Jennifer Anderson, The University of Texas, USA
Dr. Jay J. Liao, University of Washington Medical Center, USA	Prof. Dr. Wendell G. Yarbrough, University of North Carolina, USA	Dr. Joshua D. Smith, University of Pittsburgh Medical Center, USA

Register for this webinar for free here!

“Enhancing Patient Outcomes in Head and Neck Cancer Radiotherapy: Integration of Electronic Patient-Reported Outcomes and Artificial Intelligence-Driven Oncology Care Using Large Language Models”
by ChihYing Liao, ChinNan Chu, TingChun Lin, TzuYao Chou and MengHsiun Tsai
Cancers 2025, 17(14), 2345; https://doi.org/10.3390/cancers17142345

“Advancing Head and Neck Cancer Therapies: From Conventional Treatments to Emerging Strategies”
by Aleksandra Mordzińska-Rak, Ilona Telejko, Grzegorz Adamczuk, Tomasz Trombik, Andrzej Stepulak and Ewa Błaszczak
Biomedicines 2025, 13(5), 1046; https://doi.org/10.3390/biomedicines13051046

“The Role of Dysphagia on Head and Neck Cancer Patients’ Quality of Life, Functional Disabilities and Psychological Distress: Outcomes of Cancer Rehabilitation from an Observational Single-Center Study”
by Špela Matko, Christina Knauseder, David Riedl, Vincent Grote, Michael J. Fischer, Samuel Moritz Vorbach, Karin Pfaller-Frank, Wilhelm Frank and Thomas Licht
Curr. Oncol. 2025, 32(4), 220; https://doi.org/10.3390/curroncol32040220

“PDLIM3 Regulates Migration and Invasion of Head and Neck Squamous Cell Carcinoma via YAP–Mediated Epithelial–Mesenchymal Transition”
by Fan Yang, Ying Zhou, You Zhang, Weideng Wei, Fei Huang, Dan Yang, Yixin Zhang, Ruiyang Zhang, Xiaoqiang Xia, Qianming Chen et al.
Int. J. Mol. Sci. 2025, 26(7), 3147; https://doi.org/10.3390/ijms26073147

“Inflammatory Biomarkers and Oral Health Disorders as Predictors of Head and Neck Cancer: A Retrospective Longitudinal Study”
by Amr Sayed Ghanem, Kitti Sipos, Ágnes Tóth and Attila Csaba Nagy
Int. J. Mol. Sci. 2025, 26(5), 2279; https://doi.org/10.3390/ijms26052279

“Trends in Incidence and Mortality of Head and Neck Cancer Subsites Among Elderly Patients: A Population-Based Analysis”
by Małgorzata Wierzbicka, Wioletta Pietruszewska, Adam Maciejczyk and Jarosław Markowski
Cancers 2025, 17(3), 548; https://doi.org/10.3390/cancers17030548

“Recurrent and Metastatic Head and Neck Cancer: Mechanisms of Treatment Failure, Treatment Paradigms, and New Horizons”
by William T. Barham, Marshall Patrick Stagg, Rula Mualla, Michael DiLeo and Sagar Kansara
Cancers 2025, 17(1), 144; https://doi.org/10.3390/cancers17010144

“Identification of Biomarkers for Diagnosis and Prognosis of Head and Neck Cancer: Bioinformatics Approach”
by Alexandra Fernandes and Rui Vitorino
Targets 2024, 2(4), 470-480; https://doi.org/10.3390/targets2040026

“Clinical Evidence of Methods and Timing of Proper Follow-Up for Head and Neck Cancers”
by Riccardo Gili, Simone Caprioli, Paola Lovino Camerino, Gianluca Sacco, Tommaso Ruelle, Daria Maria Filippini, Silvia Pamparino, Stefania Vecchio, Filippo Marchi, Lucia Del Mastro et al.
Onco 2024, 4(4), 275-286; https://doi.org/10.3390/onco4040020

“Artificial Intelligence in Head and Neck Cancer: Innovations, Applications, and Future Directions”
by Tuan D. Pham, Muy-Teck Teh, Domniki Chatzopoulou, Simon Holmes and Paul Coulthard
Curr. Oncol. 2024, 31(9), 5255-5290; https://doi.org/10.3390/curroncol31090389

“The Advances in Proton Therapy in Head-and-Neck Cancers” Guest Editors: Dr. Nancy Lee and Dr. Edward Christopher Dee Deadline for manuscript submissions: 31 May 2026	“Decoding and Remodeling the Suppressive Tumor Immune Microenvironment in Head and Neck Cancer” Guest Editors: Dr. Andrew G. Sikora and Dr. Jennifer L. Anderson Deadline for manuscript submissions: 20 June 2026
“The Role of Targeted Therapy in Head and Neck Cancers” Guest Editor: Dr. Rikki A.M. Brown Deadline for manuscript submissions: 30 June 2026	“Molecular Targets for HPV-Related Head and Neck Cancer” Guest Editor: Dr. Joshua D. Smith Deadline for manuscript submissions: 31 October 2026
“Head and Neck Cancer: From Mechanisms to Therapeutic Approaches—Advances and Challenges” Guest Editors: Dr. Barbara Verro, Dr. Carmelo Saraniti and Dr. Daniela Carlisi Deadline for manuscript submissions: 31 October 2026	“Targeting Head and Neck Cancer: From Tumor Microenvironment to Therapy Resistance” Guest Editors: Prof. Dr. Ratna B. Ray and Dr. Subhayan Sur Deadline for manuscript submissions: 15 November 2026

To commemorate World Cancer Day 2026, MDPI is pleased to introduce the “World Cancer Day 2026 Webinar Series”. Reflecting the global theme “United by Unique”, this series highlights how every story, discovery, and voice contributes to strengthening the global fight against cancer.

In our April session, we welcome leading voices in head and neck cancer research to share impactful insights, raise awareness, and highlight recent advances in prevention, diagnosis, and treatment.

Through this series, we aim to empower the global community with knowledge, inspire collaboration, and support ongoing efforts to address cancer worldwide. Together, we honor every patient’s journey, recognize every researcher’s contribution, and reinforce the power of collective action in the fight against cancer.

Date: 30 April 2026
Time: 17:00 CEST | 11:00 EDT | 23:00 CST Asia
Webinar ID: 824 5069 5488
Webinar Secretariat: journal.webinar@mdpi.com
Website: https://sciforum.net/event/WCD2026-3

Register now for free!

After registering, you will receive a confirmation email on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.

Unable to attend? Register anyway, and we will let you know when the recording is available for viewing.

Webinar Keynote Speakers:

• Dr. Kousik Kumar Kesh, Department of Pathology, St. Louis University, USA;
• Dr. Richard Yuxiong Su, Division of Oral and Maxillofacial Surgery, The University of Hong Kong, Hong Kong S.A.R, China;
• Dr. Jennifer Anderson, MD Anderson Cancer Center, University of Texas, USA;
• Dr. Jay J. Liao, Fred Hutchinson Cancer Center, Department of Radiation Oncology, University of Washington Medical Center, USA;
• Dr. Wendell G. Yarbrough, Department of Otolaryngology (Head and Neck Surgery), School of Medicine, University of North Carolina, USA;
• Dr. Joshua D. Smith, Department of Otolaryngology (Head and Neck Surgery), University of Pittsburgh Medical Center, USA.

Conference: BOOS Conference 2026
Organizer: British Orthopaedic Oncology Society
Date: 4–5 June 2026
Location: London, UK

A number of MDPI journals will be attending BOOS 2026 as exhibitors. This meeting will be held in London, UK, from 4 to 5 June 2026.

The British Orthopaedic Oncology Society (BOOS) annual conference plays a pivotal role in advancing the field of orthopaedic oncology in the United Kingdom. This prestigious event serves as a platform for leading experts, researchers, and healthcare professionals to come together, exchange knowledge, and discuss the latest developments in the diagnosis, treatment, and care of patients with musculoskeletal tumours. Through a combination of keynote lectures, interactive sessions, and networking opportunities, the conference fosters collaboration, facilitates the dissemination of cutting-edge research, and promotes the highest standards of patient care. It is a cornerstone of BOOS’s commitment to continuous education, innovation, and improving outcomes for individuals affected by orthopaedic oncological conditions.

The following MDPI journals will be represented at the conference:

• Cancers;
• Onco;
• Osteology.

If you are planning to attend the above conference, please feel free to stop by our booth. Our delegates look forward to meeting you in person to answer any questions that you may have.

For more information about the conference, please visit the following website: https://boos.org.uk/services/boos-2026.

We are honored to announce that Prof. Dr. William Gerwick will serve as the Chair of the 2026 Tu Youyou Award Committee.

A world-renowned authority in marine natural products chemistry and pharmacology, Professor Gerwick is a Distinguished Professor at both the Scripps Institution of Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego (UCSD). His pioneering work at the intersection of ocean sciences and drug discovery makes him a fitting leader for an award centered on transformative medicinal breakthroughs.

Under Professor Gerwick’s stewardship, the 2026 Tu Youyou Award Committee will focus on recognizing innovative and impactful research in natural products chemistry and medicinal chemistry, particularly work with the potential to drive meaningful advances in both scientific understanding and human health.

To provide further insight into his perspectives, we include below an interview with Professor Gerwick, in which he reflects on his scientific journey, his views on the field, and his vision for the Tu Youyou Award.

A Conversation with the Chair

1. Could you please introduce yourself and your research journey?

My research focuses on the natural products of marine algae and cyanobacteria, their application in medicine, their biosynthesis using genomic approaches, and innovative methods in the structure elucidation of natural products.

I received my BS degree from the University of California at Davis, my PhD from the University of California at San Diego, and conducted postdoctoral work at the University of Connecticut. After a couple of years in a junior faculty position at the Department of Chemistry at the University of Puerto Rico, I spent 21 years as Professor of Pharmacy at Oregon State University. In 2005, I returned to my PhD institution at the Scripps Institution of Oceanography and the Skaggs School of Pharmacy and Pharmaceutical Sciences at UC San Diego, where I am currently a Distinguished Professor of Oceanography and Pharmaceutical Sciences.

Throughout my career, I have been dedicated to advancing the field through both leadership and mentorship. I have served as president of the American Society of Pharmacognosy, chaired and co-chaired several major research conferences, and served as an associate editor for the Journal of Natural Products. I am a Fellow of the American Association for the Advancement of Science (AAAS) and of the American Society of Pharmacognosy. I have trained over 100 doctoral and postdoctoral students, and my research group has published nearly 500 papers and more than 25 patents on topics in the natural product sciences and medicinal chemistry.

2. What motivated you to accept the role of Chair of the 2026 Tu Youyou Award Committee?

Of course, I am a huge supporter of all awards that are given in recognition of excellent scientific research, and especially so in the natural products sciences and medicinal chemistry. However, this award is truly special in that it recognizes scientific excellence as well as impact, and is given in the name of an individual, Tu Youyou, who clearly had many challenges along the path to reach the pinnacle of her success. Not only was she the first Chinese person to win a Nobel prize in this area, but she was also the first Chinese woman to receive a Nobel prize, and this was achieved without graduate education in China or elsewhere. It’s a true testament to what can be achieved by hard work, determination, and vision. To read the history of her extraordinary approach to discovering novel antimalarial compounds from Traditional Chinese Medicine is truly inspirational. It is, therefore, the inspiration provided by the extraordinary life and career of Tu Youyou that motivated me to accept the Chair of the Award Committee for 2026.

3. How do you view the role of natural products chemistry and medicinal chemistry in today’s scientific landscape, and what major advances over the past decade have shaped this field?

A quite remarkable integration of fields is currently transforming natural products science and medicinal chemistry. In natural products, we are seeing integration of different omics methods, from metabolites to proteins to nucleic acids. Sophisticated biological and pharmacological approaches are driving the discovery of exquisitely potent and selective natural products. Advances are being made to integrate molecular-level recognition of natural products with chemical ecological studies, and sophisticated methods of structure determination using Artificial Intelligence or pioneering new tools such as microED are being applied with increasing frequency. High-level synthetic methodologies, such as protecting group-free synthetic routes, are enhancing medicinal chemistry, accelerating the identification of lead molecules with attractive pharmaceutical properties at an increasing pace.

4. How do you consider the balance between fundamental discovery (e.g., new molecules or mechanisms) and practical impact (e.g., therapeutic applications)?

Many individuals are excellent scientists and mentors, and have essential roles in developing our culture that values science and the scientific method. It should also be pointed out that not all scientific discoveries are going to have a broad societal impact, but they are nevertheless critical to the overall body and structure of science. But it is a truly remarkable individual who makes a key scientific discovery, recognizes its potential value to society in general, and then has the skills and determination to bring it forward as a useful product. That was the type of person the Tu Youyou is, and that is the type of person who is honored by the prize in her name.

5. What do you see as the key challenges or opportunities currently facing the field?

We are on the crux of an amazing revolution in many of the sciences, including natural products and medicinal chemistry; the purposeful application of Artificial Intelligence to solving many of the difficulties involved in the search for new pharmaceuticals from Nature. AI is transforming how we select organisms for study, what pharmaceutical targets to go after, rapidly resolving the chemical structures of new compounds, identifying efficient routes to their chemical synthesis, understanding their molecular mechanisms of action, and finally, designing their clinical application. The role of people in these pursuits is changing. Increasingly, the human role will be providing overall vision: what can we do? What should we do? And it is important to remember that AI is providing hypotheses, not truth. Scientists with expert domain knowledge will be critical for discerning the correctness of hypotheses put forth by AI. Altogether, advances in technology, expanding knowledge, and the appropriate use of AI methods are preparing society to be able to address emerging diseases, such as pandemics, as well as conditions that are not effectively treated by currently existing therapeutics.

6. How do you expect the Tu Youyou Award to contribute to the advancement of natural product chemistry, medicinal chemistry, and human health over the coming years?

The Tu Youyou Award is potentially transformative for the broad fields of natural products science and medicinal chemistry as it brings a significantly increased level of visibility to these topics and their contributions to human health. It will be crucial to have excellent communication to news agencies, social media and other communication outlets so that the general public is informed and educated on the high impact of these natural product/medicinal chemistry contributions. This will bring increased funding, attract promising students, and generally enrich the interface of these fields with the health sector.

7. What message would you like to convey to the research community and the public during this open nomination phase?

This prize gives broad societal visibility to the role that natural products have had in shaping a majority of our current medicines, as well as understanding the life forms with whom we share the planet. Further, it recognizes a woman scientist working under sub-optimal conditions who could persevere and make discoveries of global impact. The prize and what it represents, therefore, inspires current and future generations to engage in the study of Nature and its relationship to Human Health, to overcome adversity, and to aspire to making one’s life impactful.

About the Tu Youyou Award

Established in 2016, the Tu Youyou Award seeks to honor those who excel in the fields of natural products chemistry and medicinal chemistry. This award offers a total prize of CHF 100,000, which will be equally divided among the winners if there is more than one, with each recipient receiving an award medal and a certificate.

The 2026 Tu Youyou Award is open for nominations until 31 October 2026. We encourage all eligible candidates to participate in this prestigious recognition, as this award not only honors individual achievement but also encourages further scientific exchange, exploration and discovery in critical areas of medicine.

If you are interested in participating, please visit the Tu Youyou Award website for more information on the nomination requirements.

Conference: The 2026 Annual Congress of the European Association for Cancer Research
Date: 8–11 June 2026
Location: Budapest, Hungary

We are pleased to announce that MDPI will participate in the 2026 Annual Congress of the European Association for Cancer Research (EACR 2026), held in Budapest, Hungary, from 8 to 11 June 2026.

The 2026 Annual Congress of the European Association for Cancer Research (EACR 2026) is a four-day congress dedicated to basic, preclinical and translational cancer research across a wide range of topics. The conference will highlight the latest research and bring together the cancer research community to inspire innovation and build knowledge, connections and collaborations.

The following MDPI journals will be represented at the conference:

• Cancers;
• JPM;
• Current Oncology;
• Onco;
• JCM;
• Cells;
• Diseases;
• Epigenomes;
• CIMB;
• Biologics;
• Life;
• Gastrointestinal Disorders;
• Clinics and Practice;
• DNA;
• IJMS;
• Diagnostics.

If you are planning to attend the above conference, please feel free to start an online conversation with us. Our delegates look forward to meeting you in person at booth #101 and answering any questions that you may have. For more information about the conference, please visit the following website: https://2026.eacr.org/.

Our portfolio of journals available for publishing up-to-date research in immediate open access format has been further expanded. In the first quarter of 2026, nine new journals released their inaugural issues and three transferred journals released their first issue as part of MDPI, covering the subjects of clinical medicine, chemistry, computer science & mathematics, engineering, environment & ecology, and social sciences & psychology.

We extend our gratitude to the Editors-in-Chief, Associate Editors, and Editorial Board Members who will shape the future course of these brand-new journals. Each journal is dedicated to upholding strong editorial standards through a thorough peer review process, ensuring impactful open access scholarship.

Please feel free to browse and discover more about the new journals below.

We would like to thank everyone who has supported the development of open access publishing. If you would like to create a new journal, you are welcome to send an application here or contact the New Journal Committee (newjournal-committee@mdpi.com).

As part of its ongoing commitment to advancing cancer research and knowledge exchange, MDPI highlights colorectal cancer in the March edition—one of the most prevalent and deadly cancers worldwide. It ranks as the third most diagnosed cancer and the second leading cause of cancer-related deaths globally, with an estimated 1.9 million new cases and over 900,000 deaths each year.

Of growing concern is the steady rise in incidence among individuals under 50, a trend observed over the past two to three decades. This underscores the urgent need to better understand underlying risk factors, strengthen early detection strategies, and develop innovative diagnostic tools.

Through curated research, Special Issues, and expert-led webinars, MDPI journals continue to support collaboration across researchers, clinicians, and policymakers. Such collective efforts are essential to accelerate discoveries and translate them into meaningful action—advancing toward more effective prevention, earlier detection, and improved patient outcomes.

Keynote Speakers
Prof. Dr. Paola Patrignani, “G. d’Annunzio” University School of Medicine, Italy	Prof. Dr. William Gmeiner, Wake Forest University, USA	Dr. Eva Martínez-Balibrea, Catalan Institute of Oncology, Spain	Dr. Zoltán Wiener, Semmelweis University, Hungary

Register for this webinar for free here!

“Integrative Mechanistic Investigation of the Anticancer Effects of Panax notoginseng in Colorectal Cancer”
by Jaemoo Chun, Sarah Shin and Jeeyoun Jung
Molecules 2026, 31(5), 807; https://doi.org/10.3390/molecules31050807  

“Integrated Multi-Omics Analysis Identifies Novel Prognostic and Diagnostic Hub Genes in Colorectal Cancer”
by Devi Lal and Himani Pandey
Onco 2025, 5(4), 50; https://doi.org/10.3390/onco5040050

“A Multimodal MRI-Based Model for Colorectal Liver Metastasis Prediction: Integrating Radiomics, Deep Learning, and Clinical Features with SHAP Interpretation”
by Xin Yan, Furui Duan, Lu Chen, Runhong Wang, Kexin Li, Qiao Sun and Kuang Fuby Xin Yan, Furui Duan, Lu Chen, Runhong Wang, Kexin Li, Qiao Sun and Kuang Fu
Curr. Oncol. 2025, 32(8), 431; https://doi.org/10.3390/curroncol32080431  

“Exploring Experimental Models of Colorectal Cancer: A Critical Appraisal from 2D Cell Systems to Organoids, Humanized Mouse Avatars, Organ-on-Chip, CRISPR Engineering, and AI-Driven Platforms—Challenges and Opportunities for Translational Precision Oncology”
by Ahad Al-Kabani, Bintul Huda, Jewel Haddad, Maryam Yousuf, Farida Bhurka, Faika Ajaz, Rajashree Patnaik, Shirin Jannati and Yajnavalka Banerjee
Cancers 2025, 17(13), 2163; https://doi.org/10.3390/cancers17132163

“The Gut Microbiota and Colorectal Cancer: Understanding the Link and Exploring Therapeutic Interventions”
by Imen Zalila-Kolsi, Dhoha Dhieb, Hussam A. Osman and Hadjer Mekideche
Biology 2025, 14(3), 251; https://doi.org/10.3390/biology14030251

“A Novel Bacteriophage with the Potential to Inhibit Fusobacterium nucleatum-Induced Proliferation of Colorectal Cancer Cells”
by Ho Yin Pekkle Lam, Meng-Jiun Lai, Pin-Chun Wang, Wen-Jui Wu, Li-Kuang Chen, Hsiang-Wei Fan, Chun-Chieh Tseng, Shih-Yi Peng and Kai-Chih Chang
Antibiotics 2025, 14(1), 45; https://doi.org/10.3390/antibiotics14010045

“A New Blood-Based Epigenetic Diagnostic Biomarker Test (EpiSwitch^®® NST) with High Sensitivity and Positive Predictive Value for Colorectal Cancer and Precancerous Polyps”
by Ewan Hunter, Heba Alshaker, Cicely Weston, Mutaz Issa, Shekinah Bautista, Abel Gebregzabhar, Anya Virdi, Ann Dring, Ryan Powell, Jayne Green et al.
Cancers 2025, 17(3), 521; https://doi.org/10.3390/cancers17030521

“The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives”
by Mitsunobu Takeda, Shoma Yoshida, Takuya Inoue, Yuki Sekido, Tsuyoshi Hata, Atsushi Hamabe, Takayuki Ogino, Norikatsu Miyoshi, Mamoru Uemura, Hirofumi Yamamoto, Yuichiro Doki and Hidetoshi Eguchi
Cancers 2025, 17(3), 428; https://doi.org/10.3390/cancers17030428

“Network Pharmacology and Bioinformatics Study of Six Medicinal Food Homologous Plants Against Colorectal Cancer”
by Xinyue Zhao, Jian Xiu, Hengzheng Yang, Weiwei Han and Yue Jin
Int. J. Mol. Sci. 2025, 26(3), 930; https://doi.org/10.3390/ijms26030930

“A Review of Potential Agents for Colon Cancer Interception in FAP Patients: Evidence from Preclinical Studies in APC^Min/+ Mice”
by Karthikkumar Venkatachalam, Krishnendu Goswami, Venkateshwar Madka and Chinthalapally V. Rao
Targets 2025, 3(1), 4; https://doi.org/10.3390/targets3010004

“Colorectal Cancer: Epidemiology, Risk Factors, and Prevention”
by Gholamreza Roshandel, Fatemeh Ghasemi-Kebria and Reza Malekzadeh
Cancers 2024, 16(8), 1530; https://doi.org/10.3390/cancers16081530

“Symptom Burden and Time from Symptom Onset to Cancer Diagnosis in Patients with Early-Onset Colorectal Cancer: A Multicenter Retrospective Analysis”
by Victoria A. Baronas, Arif A. Arif, Eric Bhang, Gale K. Ladua, Carl J. Brown, Fergal Donnellan, Sharlene Gill, Heather C. Stuart and Jonathan M. Loree
Curr. Oncol. 2024, 31(4), 2133-2144; https://doi.org/10.3390/curroncol31040158

“Recent Advances in Surgical Strategies for Managing Metastatic Colorectal Cancer” Guest Editors: Dr. Fabrizio D'Acapito and Dr. Marco Vaira Deadline for manuscript submissions: 15 June 2026	“Novel Strategies in the Prevention/Treatment of Colorectal Cancer: 2nd Edition” Guest Editor: Prof. Dr. William H. Gmeiner Deadline for manuscript submissions: 20 June 2026
“Molecular Mechanisms and Therapeutic Strategies of Colorectal Cancer” Guest Editor: Dr. Daniel Gabriel Pons Deadline for manuscript submissions: 20 September 2026	“Gut Microbiota and Inflammation in Colorectal Tumor Development and Progression” Guest Editors: Prof. Dr. Giovanni Monteleone and Dr. Irene Marafini Deadline for manuscript submissions: 30 September 2026